NEWT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NEWT is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is near its pre-market price of 13.36, but the technical setup is mixed, analyst sentiment is only neutral, and there are no strong fresh catalysts. If the investor is impatient and wants to act now, I would still not call this a buy; the better choice is to hold and wait for clearer confirmation or a better entry.
The trend is mixed. On the bullish side, SMA 5 is above SMA 20 and SMA 200, which supports the broader trend. However, MACD histogram is -0.0428 and negatively expanding, showing near-term momentum is weakening. RSI_6 at 47.4 is neutral, so there is no oversold buy signal. The current pre-market price of 13.36 is just above the reported current option-linked price of 13.1 and near pivot resistance at 13.399, suggesting limited immediate upside unless it breaks above 14.064 resistance first.
["Pre-market trading is positive at 13.36, up 1.98%.", "Bullish moving average structure: SMA 5 > SMA 20 > SMA 200.", "Options positioning is call-heavy with a 0.19 open interest put-call ratio.", "Analyst price target was raised to 13 from 12."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "MACD is negative and weakening, indicating short-term momentum deterioration.", "Analyst rating remains only Market Perform, which is not a bullish conviction view.", "Insiders are neutral and hedge funds are neutral, with no significant accumulation trends.", "No recent congress trading data and no notable politician/influencer buying support.", "High implied volatility suggests elevated expectation, but not necessarily attractive entry quality."]
No usable latest-quarter financial snapshot was provided because of a data error, so I cannot confirm the most recent quarter season or quantify growth trends. Based on the available dataset, there is no current financial update to support a stronger buy case.
Keefe Bruyette raised the price target on NewtekOne to 13 from 12 on 2026-05-01 and kept a Market Perform rating. That is a mildly positive target revision, but the actual recommendation remains neutral. Wall Street’s pros view is limited upside support from the target increase, while the cons view is that the stock still lacks a bullish consensus and is not rated Outperform by this analyst.
